Objectives
To determine if HIV positive pregnant women who receive both sulfadoxine-pyrimethamine (SP) for malaria prophylaxis and Highly Active Antiretroviral Therapy (HAART) have a different risk of having a low birth weight (LBW) infant (<2500 grams) than women receiving only HAART, only SP, or neither drug.
Methods
We conducted a retrospective cohort analysis of HIV positive pregnant women with both antenatal and delivery information recorded in the Zambia Electronic Perinatal Record System (ZEPRS) database who had an initial antenatal care visit between February 2006 and December 2012 in Lusaka, Zambia. We compared maternal and newborn characteristics among women receiving both SP and HAART, HAART only, SP only, or neither drug. A log binomial regression model including a term for the interaction between SP and HAART treatment was used to estimate the risk ratio (RR) for the association between the interaction of SP and HAART treatment and LBW.
Methods
We conducted a retrospective cohort analysis of HIV positive pregnant women with both antenatal and delivery information recorded in the Zambia Electronic Perinatal Record System (ZEPRS) database who had an initial antenatal care visit between February 2006 and December 2012 in Lusaka, Zambia. We compared maternal and newborn characteristics among women receiving both SP and HAART, HAART only, SP only, or neither drug. A log binomial regression model including a term for the interaction between SP and HAART treatment was used to estimate the risk ratio (RR) for the association between the interaction of SP and HAART treatment and LBW.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
